Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPC-12759 vs Sodium Hyaluronate in Keratoconjunctival Epithelial Disorder
NCT01493180Phase 2Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Dec 2011
- Primary completion
- Nov 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of rebamipide ophthalmic solution in Keratoconjunctivitis (KC) and dry eye syndrome (DED) (2 arms), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoint: Change in the Keratoconjunctival Staining Score From Baseline at 4 weeks. Started Dec 2011; status: completed.
02
Drugs
rebamipide ophthalmic solution
03
Conditions
Keratoconjunctivitis (KC)dry eye syndrome (DED)
Beyond the preview
Go deeper on NCT01493180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01493180.